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Plasticity of excitatory synapses onto striatal projec-
tion neurons (MSNs) has the potential to regulate
motor function by setting the gain on signals driving
both direct- and indirect-pathway basal ganglia
circuits. Endocannabinoid-dependent long-term
depression (eCB-LTD) is the best characterized
form of striatal plasticity, but the mechanisms gov-
erning its normal regulation and pathological dysre-
gulation are not well understood. We characterized
two distinct signaling pathways mediating eCB
production in striatal indirect-pathway MSNs and
found that both pathways were modulated by dopa-
mine D2 and adenosine A2A receptors, acting
through cAMP/PKA. We identified regulator of G
protein signaling 4 (RGS4) as a key link between
D2/A2A signaling and eCB mobilization pathways.
In contrast to wild-type mice, RGS4/ mice ex-
hibited normal eCB-LTD after dopamine depletion
and were significantly less impaired in the 6-OHDA
model of Parkinson’s disease. Taken together, these
results suggest that inhibition of RGS4 may be
an effective nondopaminergic strategy for treating
Parkinson’s disease.
INTRODUCTION
The basal ganglia are a network of subcortical brain nuclei
engaged in many aspects of motor function, including action
selection and adaptive motor learning (Graybiel et al., 1994;
Hikosaka et al., 2000; Packard and Knowlton, 2002; Yin and
Knowlton, 2006). Information enters the basal ganglia through
the striatum, whose principal neurons (medium spiny neurons
[MSNs]) receive highly convergent excitatory input from the
cortex and thalamus (Bolam et al., 2000). The excitatory
synapses formed onto MSNs are an important site of long-
term plasticity in the basal ganglia network (Kreitzer and
Malenka, 2008; Lerner and Kreitzer, 2011; Surmeier et al.,2009). This plasticity has the potential to powerfully regulate
basal ganglia circuit function, and therefore motor function, by
setting the gain on incoming cortical and thalamic signals.
Defects in striatal plasticity are thought to play a role in many
movement disorders, including Parkinson’s disease, Hunting-
ton’s disease, and dystonia (Kitada et al., 2007, 2009; Kreitzer
and Malenka, 2007; Kurz et al., 2010; Peterson et al., 2010;
Shen et al., 2008).
Despite its functional importance, the molecular mechanisms
underlying striatal plasticity remain elusive. The best-studied
form of striatal plasticity is endocannabinoid-dependent LTD
(eCB-LTD). This form of LTD is induced following the production
and release of endocannabinoids (eCBs) from the postsynaptic
neuron, which then act on presynaptic CB1 receptors to lower
neurotransmitter release probability. Although eCB-LTD is
observed in both subtypes of MSNs (Shen et al., 2008), it can
be most reliably induced in vitro at excitatory synapses onto
indirect-pathway MSNs (Kreitzer and Malenka, 2007), which
express dopamine D2 and adenosine A2A receptors. There are
several postsynaptic membrane proteins that are required to
elicit eCB release sufficient to induce indirect-pathway eCB-
LTD: group I (Gq-coupled) metabotropic glutamate receptors
(mGluRs), L-type voltage-gated calcium channels (L-VGCCs),
and dopamine D2 receptors (Calabresi et al., 1994, 1997; Choi
and Lovinger, 1997; Kreitzer and Malenka, 2005; Sung et al.,
2001). Adenosine A2A receptors are also able to modulate
indirect-pathway LTD (Lerner et al., 2010; Shen et al., 2008).
Previous work has established the importance of postsynaptic
activation of group I mGluRs and L-VGCCs (Calabresi et al.,
1994; Choi and Lovinger, 1997; Sung et al., 2001), yet it is not
known how the signaling pathways of these two membrane
proteins interact. It has also been proposed that phospho-
lipase Cb (PLCb) is a coincidence detector for group I mGluR
activation of Gq signaling and calcium influx through L-VGCCs
(Fino et al., 2010; Hashimotodani et al., 2005). However, the
precise role of PLCb in striatal eCB-LTD is not clear (Adermark
and Lovinger, 2007).
Similarly, it remains unclear why activation of D2 receptors is
required for eCB-LTD and blockade of A2A receptors enhances
it. One study indicated that D2 receptors act via adenylyl
cyclase 5 (Kheirbek et al., 2009), but what occurs downstream
of cAMP production is not known. Other studies haveNeuron 73, 347–359, January 26, 2012 ª2012 Elsevier Inc. 347
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located on MSNs or on cholinergic interneurons (Tozzi et al.,
2011; Wang et al., 2006).
Understanding how dopamine receptors control striatal func-
tion is especially important in the context of Parkinson’s disease,
where dopaminergic input to the striatum is lost. For many
decades, Parkinson’s patients have been treated with the dopa-
mine precursor levodopa and more recently with dopamine
receptor agonists (typically D2-receptor-specific agonists).
While this direct approach of dopamine replacement is
extremely helpful in relieving symptoms early in the disease
process, as the disease progresses its efficacy wanes and side
effects often develop. A better understanding of how dopamine
acts in the striatum could lead to new strategies for treating
Parkinson’s disease symptoms downstream of dopamine
receptors.
Ultimately, the signaling pathways of group I mGluRs, L-
VGCCs, D2 receptors and A2A receptors must converge to
control the postsynaptic mobilization of eCBs. However, the
specific pathways underlying eCB mobilization for striatal
LTD—and the putative eCB produced—are not clear. There
are two major candidates for the eCB produced: (1) anandamide
(AEA), thought to be produced by phospholipase D (PLD)
activity, and (2) 2-arachidonoylglycerol (2-AG), thought to be
produced by PLCb and DAG lipase (Ahn et al., 2008; Piomelli,
2003). Much of the available evidence has supported the role
of AEA in indirect-pathway LTD (Ade and Lovinger, 2007; Giuf-
frida et al., 1999; Kreitzer and Malenka, 2007). However, 2-AG
can also mediate LTD (Fino et al., 2010; Lerner et al., 2010).
Additionally, 2-AG appears to be the major signaling eCB for
plasticity in other brain areas, as well as for short-term eCB-
dependent plasticity in the striatum (Gao et al., 2010; Tanimura
et al., 2010; Uchigashima et al., 2007).
In this study, we outline a model of striatal eCB production
that clarifies the role of group I mGluRs, internal calcium stores,
and L-VGCCs during LTD induction by both low- and high-
frequency stimulation protocols. We also provide a mechanism
for the control of eCB production by D2 and A2A receptors in
striatal MSNs. Specifically, we find that a GTPase-activating
protein called regulator of G protein signaling 4 (RGS4) links
D2 and A2A signaling to group I mGluR signaling. These findings
unify a number of previously disparate findings related to striatal
eCB-LTD, and raise the possibility of new nondopaminergic
drugs to treat Parkinson’s disease.
RESULTS
PLCb-Dependent and -Independent Forms of eCB-LTD
Can Be Elicited at Excitatory Synapses onto Striatal
Indirect-Pathway MSNs
To study the mechanisms of eCB-LTD in indirect-pathway
MSNs, we began by confirming that high-frequency stimulation
(HFS; 100 Hz) of excitatory afferents to indirect-pathway
MSNs in the dorsolateral striatum causes eCB-LTD when paired
with postsynaptic depolarization (48% ± 2% of baseline at
30–40 min in control conditions; 97% ± 6% in the cannabinoid
CB1 receptor antagonist AM251; p < 0.05; Figures 1A and 1B).
We also confirmed that HFS-LTD is dependent on group I348 Neuron 73, 347–359, January 26, 2012 ª2012 Elsevier Inc.(Gq-coupled) mGluRs by bath application of the group I mGluR
antagonist AIDA (96% ± 12%, p < 0.05 compared to control;
Figure 1C). Next, we tested potential signaling pathways down-
stream of Gq. The canonical target of Gq is PLCb (Hubbard and
Hepler, 2006; Taylor et al., 1991). Surprisingly, we were unable
to block HFS-LTD by including the PLC inhibitor U73122 in the
intracellular recording solution (54% ± 5%; Figure 1C). This
finding was unexpected because other groups have demon-
strated that eCB-mediated depression in MSNs is PLCb-
dependent (Fino et al., 2010; Hashimotodani et al., 2005; Jung
et al., 2005; Yin and Lovinger, 2006) although not in all cases
(Adermark and Lovinger, 2007). Therefore, we decided to
examine whether the PLCb-independence of HFS-LTD was
unique to that stimulation protocol.
As an alternative to HFS-LTD, we applied a low-frequency
stimulation (LFS) induction protocol that is qualitatively similar
to that used in previous studies of striatal LFS-LTD (Lerner
et al., 2010; Ronesi and Lovinger, 2005). In brief, we repeatedly
paired epochs of 20 Hz stimulation with postsynaptic depolariza-
tion over several minutes (see Experimental Procedures for
details) to induce LTD (56% ± 10%; Figures 1D and 1E). Similar
to HFS-LTD, LFS-LTD was blocked by AM251 and AIDA (95% ±
6% in AM251; 100% ± 8% in AIDA; both p < 0.05 compared to
control; Figures 1E and 1F), indicating a dependence on CB1
receptors and group I mGluRs, respectively. However, LFS-
LTD was also blocked by intracellular U73122 (102% ± 15%;
p < 0.05 compared to control; Figure 1F), indicating a role for
PLCb. Thus, both PLCb-dependent and -independent forms
of eCB-LTD can be elicited at excitatory synapses onto striatal
indirect-pathway MSNs simply by using different stimulation
frequencies and repetitions.
LFS-LTD Requires DAG Lipase But Not Elevations
in Intracellular Calcium
PLCb is an enzyme that produces the intracellular secondary
messenger diacylglycerol (DAG), which can be converted to
the eCB 2-arachidonylglycerol (2-AG) by the enzyme DAG lipase
(DAGL). The sequential activities of PLCb and DAGL represent
a well-defined pathway for 2-AG production that could mediate
LFS-LTD. To test whether DAGL is also required for LFS-LTD, we
applied the LFS-LTD induction protocol in the presence of the
DAGL inhibitor THL and observed that THL blocked LFS-LTD
(92% ± 13%; p < 0.05 compared to control; Figure 2A).
In addition to DAG, PLCb produces another important
secondary messenger, IP3, which can activate IP3 receptors
located on the endoplasmic reticulum and cause release of
calcium from internal stores. To test whether internal calcium
stores are involved in LFS-LTD, we added thapsigargin, which
depletes these stores, to our intracellular recording solution,
but this manipulation did not block LFS-LTD (47% ± 7%;
Figure 2B).
Although internal calcium stores were not required for LFS-
LTD, other sources of calcium might be important. L-type
voltage-gated calcium channels (L-VGCCs) have previously
been implicated in eCB release (Adermark and Lovinger, 2007;
Calabresi et al., 1994; Choi and Lovinger, 1997; Kreitzer and
Malenka, 2005), yet we found that the L-VGCC blocker nitrendi-
pine did not block LFS-LTD (64% ± 6%; Figure 2C). Another
Figure 1. PLCb-Dependent and -Indepen-
dent Forms of eCB-LTD Can Be Elicited at
Excitatory Synapses onto Striatal Indirect-
Pathway MSNs
(A) Schematic of the high-frequency stimulation
(HFS)-LTD induction protocol. One hundred hertz
stimulation for one second was paired with post-
synaptic depolarization to10mV. This stimulation
was repeated four times at ten second intervals.
(B) HFS-LTD in control conditions (white circles)
and in 1 mM of the CB1R antagonist AM251 (black
circles). In this, and all subsequent panels
showing LTD, normalized EPSC amplitudes are
plotted over time. Traces from representative
experiments are shown above the graph. The thin
traces show the average EPSC from 0–10 min,
and the thick traces show the average EPSC from
30–40 min. For HFS-LTD, the arrowhead indicates
the time of induction. In all panels, scale bars are
100 pA 3 5 ms and error bars are SEM.
(C) HFS-LTD in 100 mM of the mGluR1/5 antago-
nist AIDA (white circles) and with 10 mM of the
PLCb inhibitor U73122 included in the intracellular
pipette solution (black circles).
(D) Schematic of the low-frequency stimulation
(LFS)-LTD induction protocol. Twenty hertz stim-
ulation for one second was paired with post-
synaptic depolarization to 10mV. This stimula-
tion was repeated 30 times at ten second intervals
to induce LFS-LTD.
(E) LFS-LTD in control solution (white circles) and
in 5 mM AM251 (black circles). In all panels
showing LFS-LTD, the dotted line indicates the
time of LFS-LTD induction.
(F) LFS-LTD in 100 mM AIDA (white circles) and
with 10 mM U73122 included in the intracellular
solution (black circles).
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10%, n = 6, data not shown). In fact, elevations in intracellular
calcium do not appear to be strictly required for LFS-LTD, since
loading MSNs with the calcium-chelator BAPTA did not block
LFS-LTD (75% ± 10%; Figure 2C). From these experiments,
we conclude that the most likely scenario for LFS-LTD induction
is that activation of Gq-coupled mGluRs leads to activation of
PLCb, stimulating the production of DAG, which is then con-
verted to 2-AG by DAGL (Figure 2D).
HFS-LTD Requires Elevations in Intracellular
Calcium-Mediated by L-type Calcium Channels
and Calcium-Induced Calcium Release
Our initial experiments (Figure 1) showed that the pathways
underlying HFS-LTD and LFS-LTD diverge after just one step
in their induction pathways (activation of Gq by group I mGluRs).
Because HFS-LTD is PLCb-independent (Figure 1C), we pre-
dicted it would be DAGL-independent as well. Indeed, as
observed previously (Ade and Lovinger, 2007; Lerner et al.,
2010), the DAGL inhibitor THL did not block HFS-LTD (61% ±
10%; Figure 3A). We also tested whether HFS-LTD differed
from LFS-LTD in its requirements for calcium. By adding thapsi-
gargin to our intracellular solution to deplete internal calcium
stores, we found that, unlike LFS-LTD, HFS-LTD requires thesestores (117% ± 17%; p < 0.05 compared to control; Figure 3B).
Calcium from internal stores can be released into the cytoplasm
via either IP3 receptors or ryanodine receptors (RyRs). Since
HFS-LTD does not require PLCb, which produces IP3, we
reasoned that the requirement for internal calcium stores in
HFS-LTD was more likely to be dependent on RyRs than on
IP3 receptors. Indeed, when RyRs were inhibited by including
ryanodine in the intracellular solution, HFS-LTD was blocked
(108% ± 8%; p < 0.05 compared to control; Figure 3B). An IP3
receptor blocker, 2-APB, did not block HFS-LTD when included
in the intracellular solution (63% ± 10%; Figure S2A available
online).
RyRs are activated by calcium and, once activated, cause the
release of more calcium into the cytoplasm. This process of
calcium-induced calcium release (CICR) serves to amplify
calcium signals initiated by other sources of calcium influx.
What is the CICR-initiating source of calcium in HFS-LTD?
We consider L-VGCCs to be a likely source, because they are
functionally coupled to RyRs (Chavis et al., 1996) and because
L-VGCCs have previously been shown to be involved in striatal
LTD (Calabresi et al., 1994; Choi and Lovinger, 1997). In agree-
ment with this hypothesis, the L-VGCC antagonist nitrendipine
blocked HFS-LTD (92% ± 4%; p < 0.05 compared to control;
Figure 3C).Neuron 73, 347–359, January 26, 2012 ª2012 Elsevier Inc. 349
Figure 2. LFS-LTD Requires Diacylglycerol Lipase But Not Eleva-
tions In Intracellular Calcium
(A) LFS-LTD in 10 mM of the diacylglycerol lipase inhibitor THL. Gray traces in
(A), (B), and (C) show control LFS-LTD from Figure 1E for reference. In all
panels, scale bars are 100 pA 3 5 ms and error bars are SEM.
(B) LFS-LTD with 10 mMof the intracellular calcium store depleter thapsigargin
included in the intracellular solution.
(C) LFS-LTD with 10 mM of the L-type calcium channel blocker nitrendipine
(white circles) and with 10 mM of the calcium chelator BAPTA (black circles)
included in the intracellular solution.
(D) Schematic showing the proposed signaling pathway underlying LFS-LTD.
Activation of Gq-coupled mGluRs activates PLCb, stimulating the production
of diacylglycerol (DAG), which is then converted to the endocannabinoid 2-
arachidonoylglycerol (2-AG) by diacylglycerol lipase (DAGL).
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Why does HFS-LTD require group I mGluRs if it is PLCb-inde-
pendent? We reasoned that Gq must activate another enzyme
in addition to PLCb. Other direct targets of Gq include nonrecep-
tor tyrosine kinases (Bence et al., 1997). Src-family kinases are
nonreceptor tyrosine kinases that phosphorylate a number of
targets linked to eCB mobilization, including L-type calcium
channels and phospholipase D (PLD; Bence-Hanulec et al.,
2000; Henkels et al., 2010). Therefore, to test whether Src-family
kinases are required for HFS-LTD, we attempted to induce
HFS-LTD in the presence of the Src-family kinase inhibitor
PP2. PP2 completely blocked HFS-LTD (105% ± 16%; p <
0.05 compared to control; Figure 3D). To further test the hypoth-
esis that postsynaptic Src, specifically, is required for HFS-LTD,
we next included a membrane impermeable c-Src inhibitor
peptide in our intracellular recording solution. This inhibitor
peptide was also able to block HFS-LTD (88% ± 5%; p < 0.05
compared to control; Figure 3D). Notably, the Src inhibitor PP2
did not block LFS-LTD (62% ± 3%; Figure S1A), indicating that
Src acts specifically in HFS-LTD induction.
We next explored whether Src activation and the rise in intra-
cellular calcium due to L-VGCCs and CICR could be connected
to any of the known or posited PLCb-independent eCB produc-
tion pathways. Since we had already observed that inhibiting
the major 2-AG production enzyme DAGL did not block
HFS-LTD (Figure 3A), we explored a possible role for enzymes
proposed to mediate anandamide (AEA) biosynthesis. AEA can
be produced by a number of different synthesis pathways. Key
enzymes in these various pathways include PLC, PLA2, and
PLD (PLD1, PLD2, or NAPE-specific PLD; Ahn et al., 2008). A
role for any PLC isoforms had already been ruled out by our
experiments with the general PLC inhibitor U73122 (Figure 1C).
A PLA2 inhibitor, OBAA, also did not prevent HFS-LTD (57% ±
1%; Figure S2B). Finally, mice lacking NAPE-specific PLD have
intact AEA levels (Leung et al., 2006), arguing against an essen-
tial role of that PLD isoform. However, an inhibitor of PLD (with
some specificity for PLD2 over PLD1), CAY10594, significantly
blocked HFS-LTD (82% ± 5%; p < 0.05 compared to control;
Figure 3E). Another PLD inhibitor, CAY10593, also blocked
HFS-LTD to a similar degree (85% ± 10%, n = 3, data not
shown). We conclude that PLD is a key enzyme for eCB mobi-
lization in response to HFS. These data lead us to propose
a model for HFS-LTD in which activation of Gq-coupled
mGluRs leads to activation of Src, stimulating the production
Figure 3. HFS-LTD Depends on a Distinct
Signaling Pathway, Involving Src Kinase,
Internal Calcium Stores, L-type Calcium
Channels, and Phospholipase D
(A) HFS-LTD in 10 mM of the diacylglycerol lipase
inhibitor THL. Gray traces in (A)–(E) show control
HFS-LTD from Figure 1B for reference. In all
panels, scale bars are 100 pA 3 5 ms and error
bars are SEM.
(B) HFS-LTD with 10 mM of the intracellular
calcium store depleter thapsigargin included in
the intracellular solution (white circles) and with
10 mM ryanodine included in the intracellular
solution to specifically block ryanodine receptors
(black circles).
(C) HFS-LTD in 10 mM of the L-type calcium
channel blocker nitrendipine.
(D) HFS-LTD in 10 mM of the Src-family kinase
inhibitor PP2 (white circles) and with 100 mM c-Src
inhibitory peptide included in the intracellular
solution (black circles).
(E) HFS-LTD with 100 mM of the phospholipase D
(PLD) inhibitor CAY10594 (white circles).
(F) Schematic showing the proposed signaling
pathway underlying HFS-LTD. Activation of Gq-
coupled mGluRs activates Src, which phosphor-
ylates and activates L-type calcium channels
and/or PLD. Calcium influx through L-type calcium
channels (amplified by RyR-mediated calcium-
induced calcium release from internal stores) also
activates PLD. PLD activity leads to the production
and release of the endocannabinoid anandamide
(AEA).
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(Henkels et al., 2010) or by modulating L-VGCCs (Bence-Hanu-
lec et al., 2000; Figure 3F).
Dopamine D2 and Adenosine A2A Receptors Modulate
Both LFS- and HFS-LTD
Because HFS-LTD and LFS-LTD are mediated by distinct
signaling pathways downstream of Gq, we wondered whether
they are both modulated by dopamine D2 or adenosine A2A
receptors. It is established that HFS-LTD in indirect-pathway
MSNs requires dopamine D2 receptors (Kreitzer and Malenka,
2007; Shen et al., 2008). However, D2 receptor activation alone
is not sufficient to induce eCB signaling; coincident group I
mGluR activation is required (Figure S3). We confirmed that the
D2 receptor antagonist sulpiride blocked HFS-LTD (103% ±
8%; p < 0.05 compared to control; Figure 4A). Interestingly, sul-
piride was also able to inhibit LFS-LTD (88% ± 4%; p < 0.05
compared to control; Figure 4B), indicating that D2 receptors
act on eCB-LTD at or upstream of Gq.
Adenosine A2A receptors are also highly expressed in indi-
rect-pathway MSNs, where they influence eCB signaling andNeuron 73, 347–359act in opposition to D2 receptors (Shen
et al., 2008; Tozzi et al., 2007). Therefore,
we tested whether activation of A2A
receptors could block HFS- or LFS-LTD.
The A2A receptor agonist CGS21680blocked both HFS- and LFS-LTD (102% ± 7%; p < 0.05
compared to control for HFS-LTD and 90% ± 12%; p < 0.05
compared to control for LFS-LTD; Figures 4C and 4D). Thus,
like D2 receptors, A2A receptors appear to be acting at or
upstream of Gq to modulate both forms of eCB-LTD in indi-
rect-pathway MSNs. We confirmed these results in two different
BAC transgenic mouse strains (Drd2-EGFP, target EGFP-
positive MSNs; Drd1a-Tmt, target Tmt-negative MSNs), indi-
cating that D2/A2A regulation is robust across multiple mouse
lines (Figure S2C).
Dopamine D2 and Adenosine A2A Receptors Modulate
eCB-LTD through cAMP/PKA Signaling
We next considered how D2 and A2A receptors modulate eCB
mobilization and LTD. Because regulation of eCB biosynthetic
pathways by cAMP/PKA signaling is not well established, we first
tested whether D2 receptors act to promote eCB-LTD through
a reduction in cAMP levels or PKA activation. In this and sub-
sequent experiments, we utilized HFS-LTD to examine the
mechanisms regulating eCB-LTD, because this form of LTD
remains a standard in the field. To examine whether inhibition, January 26, 2012 ª2012 Elsevier Inc. 351
Figure 4. Dopamine D2 and Adenosine
A2A Receptors Modulate Both LFS- and
HFS-LTD
(A) HFS-LTD in 1 mM of the dopamine D2 receptor
antagonist sulpiride. Gray traces in (A) and (C)
show control HFS-LTD from Figure 1B for refer-
ence. In all panels, scale bars are 100 pA 3 5 ms
and error bars are SEM.
(B) LFS-LTD in 1 mM sulpiride. Gray traces in (B)
and (D) show control LFS-LTD from Figure 1E for
reference.
(C) HFS-LTD in 1 mM of the adenosine A2A
receptor agonist CGS21680.
(D) LFS-LTD in 1 mM CGS21680.
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induction, even in the presence of a D2 receptor antagonist,
we used a membrane-impermeable adenylyl cyclase inhibitor,
ddATP, and a membrane-impermeable inhibitor of PKA, PKI,
which were added to our intracellular recording solution. The
membrane-impermeability of these drugs limited their effects
to the recorded postsynaptic MSN, which allowed us to rule
out effects on cAMP/PKA-dependent processes in the presyn-
aptic terminal or in neighboring MSNs or interneurons. With
either ddATP or PKI in our intracellular recording solution, we
were able to elicit LTD in the presence of sulpiride (69% ± 9%
with sulpiride and ddATP; 71% ± 10% with sulpiride and PKI;
both p < 0.05 compared to LTD in sulpiride alone; Figure 5A).
In contrast to the action of D2 receptors, A2A receptors are
Gs-coupled receptors, and we therefore hypothesized that acti-
vation of A2A receptors blocks LTD by increasing cAMP/PKA
signaling. In support of this hypothesis, we found that reducing
cAMP/PKA activity by including either ddATP or PKI in the intra-
cellular recording solution allowed LTD to occur in the presence
of A2A agonist CGS21680 (61% ± 4% with CGS21680 and
ddATP; 65% ± 7% with CGS21680 and PKI; both p < 0.05
compared to LTD in CGS21680 alone; Figure 5B). To verify
that the LTD that occurs when cAMP/PKA signaling is inhibited
is actually eCB-LTD and not another form of synaptic plasticity,
we added the CB1 receptor antagonist AM251 to an extracellular
recording solution, which already contained CGS21680 and
patched cells with PKI included in the intracellular solution. The
addition of AM251 to the extracellular solution blocked LTD
(119% ± 16%; p < 0.05 compared to LTD with CGS21680 and
PKI; Figure S2D), demonstrating that cAMP/PKA inhibition is
allowing eCB-LTD to occur.
To further test the hypothesis that increases in cAMP/PKA
signaling are sufficient to block LTD, we tested whether directly352 Neuron 73, 347–359, January 26, 2012 ª2012 Elsevier Inc.activating either adenylyl cyclase or
PKA would block HFS-LTD when there
were no drugs present in the external
saline solution. To activate adenylyl
cyclase we used the water-soluble
(membrane-impermeable) forskolin ana-
log NKH477. To activate PKA we used
a membrane-impermeable PKA acti-
vator, Sp-8-OH-cAMPS. When either
NKH477 or Sp-8-OH-cAMPS were in-cluded in our intracellular recording solution, LTD was inhibited
(78% ± 5% with NKH477; 89% ± 9% with Sp-8-OH-cAMPS;
both p < 0.05 compared to control LTD; Figures 5C and 5D).
From these experiments, we concluded that increased cAMP/
PKA activity inhibits LTD.
D2 and A2A Receptors Regulate Striatal LTD via
Regulator of G Protein Signaling 4
How does cAMP/PKA activity block LTD? Because D2 and
A2A receptor drugs act on both LFS- and HFS-LTD, they likely
act on a common target in both pathways: group I mGluRs or
Gq. A particularly attractive candidate for such modulation is
regulator of G protein signaling 4 (RGS4). RGS4 is a GTPase-
activating protein expressed strongly in MSNs in the dorsolat-
eral striatum, where it is associated with mGluR5 and PLCb
(Gold et al., 1997; Schwendt and McGinty, 2007), its activity
is increased by PKA phosphorylation (Huang et al., 2007),
and it strongly inhibits signaling through Gq (Saugstad et al.,
1998).
To test whether RGS4 is involved in the regulation of LTD by
D2 and A2A receptors, we obtained RGS4/ mice, crossed
those mice into our D2-EGFP BAC transgenic line so that we
could identify indirect-pathway MSNs, and applied the HFS-
LTD induction protocol to indirect-pathway MSNs. In RGS4/
mice, we observed significant HFS-LTD (66% ± 5%; Figure 6A).
If RGS4 is responsible for the connection between D2 and A2A
receptor signaling and Gq signaling, then LTD in RGS4
/ mice
should occur even in the presence of the D2 antagonist sulpiride
or the A2A agonist CGS21680. Indeed, LTD was readily
observed in the presence of either drug in RGS4/ mice
(80% ± 6% in sulpiride; 64% ± 7% in CGS21680; Figure 6B).
While genetic knockouts offer complete elimination of the
gene product, they also may yield developmental and/or
Figure 5. D2 and A2A Receptors Modulate
LTD through cAMP/PKA Signaling
(A) HFS-LTD in 1 mM of the D2 receptor antagonist
sulpiride and with either 500 nM of the adenylyl
cyclase inhibitor ddATP (white circles) or 100 mM
of the PKA inhibitor PKI (black circles) in the
intracellular solution. Gray trace shows HFS-LTD
in sulpiride with no drug in the intracellular solution
from Figure 4A for reference. In all panels, scale
bars are 100 pA 3 5 ms and error bars are SEM.
(B) HFS-LTD in 1 mM of the A2A receptor agonist
CGS21680 and with either 500 nM ddATP (white
circles) or 100 mM PKI (black circles) in the intra-
cellular solution. Gray trace shows HFS-LTD in
CGS21680 with no drug in the intracellular solution
from Figure 4C for reference.
(C) HFS-LTD with 10 mM of the adenylyl cyclase
activator NKH477 in the intracellular recording
solution. Gray traces in C and D show control
HFS-LTD from Figure 1B.
(D) HFS-LTD with 0.5–1 mM of the PKA activator
Sp-8-OH-cAMPS in the intracellular recording
solution.
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small-molecule inhibitor of RGS4, CCG-63802 (Blazer et al.,
2010), to test whether acute inhibition of RGS4 could uncouple
LTD fromD2 receptors. CCG-63802was included in the intracel-
lular recording solution to restrict the drug to the postsynaptic
neuron, which also allowed us to ask whether RGS4 was acting
cell autonomously. With CCG-63802 in the pipette, the magni-
tude of LTD in control solution and in the presence of sulpiride
was indistinguishable (76% ± 10% with CCG-63802; 70% ±
12%with CCG-63802 in sulpiride; Figure 6C). Thus, we conclude
that RGS4 is acting acutely in the postsynaptic neuron to modu-
late LTD.
We also tested whether replacing RGS4 protein in indirect-
pathway MSNs from RGS4/ mice could rescue the modula-
tion of LTD by D2 and A2A receptors. We loaded different
concentrations of recombinant RGS4 protein into the pipette
and obtained whole-cell recordings from indirect-pathway
MSNs in RGS4/ mice. We found that the effects of loading
recombinant RGS4 into the MSN were highly dose-dependent
(Figure S4). A low concentration (10 pM) of RGS4 allowed LTD
to occur but did not restore the modulation of LTD by D2 and
A2A receptors seen in wild-type mice. A higher concentration
(50 pM) of RGS4, completely blocked LTD, presumably
because Gq signaling was constitutively inhibited by an excess
of RGS4. However, an intermediate concentration (25 pM)
of RGS4 did not block LTD on its own but enabled LTD to
be blocked by either sulpiride or CGS21680 (66% ± 6% with
25 pM RGS4; 84% ± 2% with 25 pM RGS4 in sulpiride;
96% ± 5% with 25 pM RGS4 in CGS21680; LTD with 25 pM
RGS4 was significantly different from LTD with 25 pM RGS4
in either sulpiride or CGS21680, p < 0.05; Figure 6D). This
result demonstrates that there is a concentration of RGS4
protein that allows for fast, dynamic regulation of its activity,likely via PKA phosphorylation (Huang et al., 2007). The fact
that replacement of RGS4 protein only in the postsynaptic
MSN was able to rescue D2 and A2A receptor modulation
of LTD in RGS4/ mice argues against developmental
defects contributing to the changes in LTD in the knockout
mice, and provides further support for a cell-autonomous
action of RGS4.
Indirect-Pathway LTD in RGS4–/– Mice Are Resistant
to Dopamine Depletion
The striatum receives dense dopaminergic innervation from the
substantia nigra pars compacta, and dopamine is required for
proper striatal function. When dopaminergic innervation of the
striatum is lost, as occurs in humans with Parkinson’s disease,
motor function is severely impaired. Similarly, when striatal
dopamine is depleted in mice by injecting the toxin 6-OHDA
into the medial forebrain bundle (where dopaminergic axons
exit the substantia nigra pars compacta), parkinsonian motor
behaviors, such as increased immobility and decreased
ambulation are observed. At least part of the inhibition of motor
function following dopamine depletion may be due to the loss
of LTD in indirect-pathway MSNs, which normally requires
dopamine D2 receptor activation (Kreitzer and Malenka,
2007). Therefore, we next tested whether LTD could be elicited
in indirect-pathway MSNs from dopamine-depleted RGS4/
mice, where activation of the dopamine D2 receptor is not
required for LTD (Figure 6B). We observed normal indirect-
pathway HFS-LTD after dopamine depletion with 6-OHDA in
RGS4/ mice (57% ± 10%), whereas in wild-type mice HFS-
LTD was absent (97% ± 11%; p < 0.05 compared to RGS4/;
Figure 6E). This finding also held true for LFS-LTD (70% ± 10%
for RGS4/ mice versus 90% ± 5% for wild-type mice; p <
0.05; Figure S1B).Neuron 73, 347–359, January 26, 2012 ª2012 Elsevier Inc. 353
Figure 6. D2 and A2A Receptors Regulate
Striatal LTD via Regulator of G Protein
Signaling 4
(A) HFS-LTD in RGS4/ mice in control (no drug)
solution (white circles) and in 1 mM of the CB1R
antagonist AM251 (black circles). Interleaved
HFS-LTD experiments in wild-type mice in control
solution are shown as open red circles. The blue
trace shows the data from HFS-LTD experiments
in wild-type mice in 1 mM AM251 from Figure 1B
for reference.
(B) HFS-LTD in RGS4/ mice in 1 mM of the A2A
receptor agonist CGS21680 (white circles) and in
1 mMof the D2 receptor antagonist sulpiride (black
circles). The solid lines showHFS-LTD in wild-type
mice in 1 mM CGS21680 (blue trace) and in 1 mM
sulpiride (red trace) from Figures 4A and 4C.
(C) HFS-LTD with 100 mM of the RGS4 inhibitor
CCG-63802 included in the intracellular solution,
in combination with either no drug (white circles) or
with 1 mM sulpiride (black circles) in the bath.
(D) HFS-LTD in RGS4/ mice with 25 pM re-
combinant RGS4 protein included in the intracel-
lular solution and with either no drug (white circles)
or with 1 mMCGS21680 (black circles) or with 1 mM
sulpiride (red circles) in the bath.
(E) HFS-LTD in dopamine-depleted slices. Slices
are from the treated hemisphere of mice injected
unilaterally with 6-OHDA in the medial forebrain
bundle. Results are shown for wild-type (white
circles) and RGS4/ mice (black circles).
(F) Schematic showing the proposed signaling
pathway bywhichD2 and A2A receptorsmodulate
eCB-LTD. In this model, D2 and A2A receptors
oppositely modulate cAMP/PKA. High PKA
activity inhibits mGluR-Gq signaling via RGS4.
Inhibition of mGluR-Gq signaling prevents the
mobilization of both 2-AG and AEA.
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Dopamine Regulates Striatal Plasticity via RGS4RGS4–/– Mice Exhibit Fewer Behavioral Deficits in
a Mouse Model of Parkinson’s Disease
Loss of indirect-pathway LTD may be a key factor in the overac-
tivity of the indirect pathway—and the concomitant reduction
in motor activity—observed after loss of striatal dopamine inner-
vation (DeLong andWichmann, 2007; Filion and Tremblay, 1991;
Obeso et al., 2000). Because RGS4/ indirect-pathway MSNs,
unlike wild-type indirect-pathway MSNs, retain the ability to
undergo LTD in dopamine-depleted conditions, we reasoned
that RGS4/ mice might have fewer behavioral deficits
following dopamine depletion. To test this hypothesis, we unilat-
erally injected 6-OHDA into the medial forebrain bundle of
RGS4/ and wild-type mice (Figure 7A). A subset of mice (of
each genotype) was injected with an equivalent volume of saline
as a control. One week after the injections, each mouse was
placed in an open field chamber for 10 min, and its movement
was monitored using video tracking software. Wild-type mice
injected with 6-OHDA had clear movement deficits when
compared to their saline-injected counterparts (Figures 7B–7F).
Overall, they moved less distance during the 10 min test period
(2,015 ± 178 cm for saline-injected wild-type mice versus
981 ± 178 cm for 6-OHDA-injected wild-type mice; p < 0.05).354 Neuron 73, 347–359, January 26, 2012 ª2012 Elsevier Inc.In contrast, RGS4/ mice treated with 6-OHDA, traveled
the same distance as their saline-injected counterparts
(2,075 ± 85 cm for saline-injected RGS4/ mice versus
1,618 ± 293 cm for 6-OHDA-injected RGS4/ mice). RGS4/
mice treated with 6-OHDA also traveled significantly more
distance than wild-type mice treated with 6-OHDA (Figure 7C).
To further dissect the changes in movement that occurred
following 6-OHDA injection, we analyzed the percentage of
time each mouse spent motionless, ambulating, or making fine
movements such as grooming. Wild-type mice that were in-
jected with 6-OHDA spent less time ambulating and more time
motionless (freezing) than wild-type mice injected with saline.
In contrast, RGS4/ mice were resistant to the motor deficits
displayed by wild-type mice (34% ± 3% of time spent making
fine movements, 56% ± 1% ambulating, 10% ± 2% freezing
for saline-injected wild-type mice; 22% ± 4% of time spent
making fine movements, 27% ± 7% ambulating, 51% ± 11%
freezing for 6-OHDA-injected wild-type mice; 25% ± 0.4% of
time spent making fine movements, 57% ± 1% ambulating,
18% ± 1% freezing for saline-injected RGS4/ mice; 23% ±
1% of time spent making fine movements, 50% ± 7% ambulat-
ing, 27% ± 7% freezing for 6-OHDA-injected RGS4/ mice;
Figure 7. RGS4–/– Mice Have Fewer Behav-
ioral Deficits in a Mouse Model of Parkin-
son’s Disease
(A) Left, example images of coronal brain slices
from wild-type (WT) and RGS4/mice stained for
tyrosine hydroxylase (TH) to verify dopamine
depletion following unilateral 6-OHDA injections.
Right, quantification of dopamine depletion in all
WT and RGS4/ mice used for behavioral anal-
ysis. The intensity of fluorescence on the ipsilateral
sidewascompared to that on thecontralateral side
for each mouse to yield the TH ipsi:contra ratio.
(B) Examples of the paths taken by dopamine-
depleted WT and RGS4/mice during the 10 min
test period. The example paths shown are from
the same mice whose TH staining is shown in (A).
(C) The distances traveled during the test period
are shown for saline-injected WT mice (n = 7), 6-
OHDA-injected WT mice (n = 12), saline-injected
RGS4/ mice (n = 6), and 6-OHDA-injected
RGS4/mice (n = 10). Data from the same group
of mice is also shown in (D), (E), and (F).
(D) The percentage of time spent freezing, am-
bulating, or making fine movements is shown for
saline-injected WT mice (n = 7), 6-OHDA-injected
WT mice (n = 12), saline-injected RGS4/ mice
(n = 6), and 6-OHDA-injected RGS4/ mice
(n = 10).
(E) Average velocity during periods of ambulation
is shown for saline-injected WT mice (n = 7), 6-
OHDA-injected WT mice (n = 12), saline-injected
RGS4/ mice (n = 6), and 6-OHDA-injected
RGS4/ mice (n = 10).
(F) Average length of an ambulation bout (time
spent continuously ambulating before stopping) is
shown for saline-injected WT mice (n = 7), 6-
OHDA-injected WT mice (n = 12), saline-injected
RGS4/ mice (n = 6), and 6-OHDA-injected
RGS4/ mice (n = 10).
(G) The average number of foot slips per trial on
the balance beam is shown for saline-injected WT
mice (n = 9), 6-OHDA-injected WT mice (n = 6),
saline-injected RGS4/ mice (n = 9), and 6-
OHDA-injected RGS4/ mice (n = 10). Data from
the same group of mice is also shown H. Three
additional 6-OHDA-injected WT mice were tested
on the balance beam, but failed to perform the
task.
(H) The average number of falls per trial on the
balance beam is shown for saline-injected WT
mice (n = 9), 6-OHDA-injected WT mice (n = 6),
saline-injected RGS4/ mice (n = 9), and 6-
OHDA-injected RGS4/ mice (n = 10).
*p < 0.05; **p < 0.01.
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Dopamine Regulates Striatal Plasticity via RGS4Figure 7D). RGS4/ mice were also resistant to deficits ob-
served in wild-type mice in ambulation velocity (5.57 ±
0.44 cm/s for saline-injected wild-type mice; 3.69 ± 0.37 cm/s
for 6-OHDA-injected wild-type mice; 5.27 ± 0.22 cm/s forNeuron 73, 347–359saline-injected RGS4/ mice; 5.10 ±
0.41 cm/s for 6-OHDA-injected RGS4/
mice; Figure 7E) and ambulation bout
length (1.60 ± 0.07 s for saline-injectedwild-type mice; 1.19 ± 0.12 s for 6-OHDA-injected wild-type
mice; 1.83 ± 0.08 s for saline-injected RGS4/ mice; 1.63 ±
0.19 s for 6-OHDA-injected RGS4/ mice; Figure 7F). Despite
improved overall movement, unilaterally 6-OHDA-injected, January 26, 2012 ª2012 Elsevier Inc. 355
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biases (Figure S5), perhaps due to remaining dopamine-depen-
dent imbalances in the function of the contralateral and ipsilat-
eral striatum. Bilateral injection of 6-OHDA caused more severe
behavioral deficits than unilateral injection, but the differences
between wild-type and RGS4/ mice were quite similar to
those observed in unilaterally injected mice (Figure S6).
Although the open field results were striking, distance traveled
is not a stringent test of motor coordination. To test for motor
coordination, we used a balance beam task in which mice
must traverse a narrow, elevated beam to reach a dark, enclosed
box (Carter et al., 1999; Fleming et al., 2004). Each mouse was
tested on three trials and foot slips on the beam as well as falls
off the beam were counted for each trial. Saline-injected wild-
type and RGS4/ mice both appeared similarly coordinated
on this task; they made very few foot slips and almost never
fell off the beam (0.67 ± 0.11 slips and 0.07 ± 0.05 falls per trial
for wild-type mice, 0.89 ± 0.09 slips and 0.03 ± 0.04 falls per trial
for RGS4/ mice; Figures 7G and 7H). 6-OHDA-injected wild-
type mice, however, were impaired. Of nine mice tested, three
could not perform the task at all. The six mice that did traverse
the beam had more foot slips and also fell off the beam signifi-
cantly more than their saline-injected counterparts (1.59 ± 0.36
slips and 1.67 ± 0.59 falls per trial; Figure 7H). They usually fell
at least once and often more than once per trial, meaning they
could not have completed the task without being placed back
onto the beam by the experimenter. In contrast, 6-OHDA-in-
jected RGS4/mice almost never slipped or fell on the balance
beam (0.33 ± 0.08 slips and 0.09 ± 0.06 falls per trial; Figure 7H).
There were no significant differences in slipping or falling
between 6-OHDA-injected RGS4/ mice and their saline-in-
jected counterparts and indeed, 6-OHDA-injected RGS4/
mice performed significantly better than 6-OHDA-injected wild-
type mice. These data indicate that RGS4/ mice are signifi-
cantly more coordinated following dopamine depletion than
wild-type mice. Furthermore, our open field and balance beam
data all support the conclusion that RGS4 is a critical link
between loss of dopamine, dysregulation of striatal eCB-LTD,
and motor impairments.
DISCUSSION
In this study, we characterized a novel mechanism linking
dopamine D2 and adenosine A2A receptor signaling to mobiliza-
tion of eCBs through theGTPase-accelerating protein RGS4.We
found that eCB-LTD can be induced by engaging either of two
distinct biosynthetic pathways, both of which require D2
receptor activation and are inhibited by A2A receptor activation.
This modulation of eCB-LTD by D2 and A2A receptors requires
RGS4, which is phosphorylated by PKA (Huang et al., 2007)
and inhibits mGluR-Gq signaling (Saugstad et al., 1998). RGS4
is therefore a key link between dopamine signaling, synaptic
plasticity, and motor behavior, and may be a promising non-
dopaminergic target for modulating basal ganglia circuitry.
Two Distinct Forms of Indirect-Pathway eCB-LTD
Our finding of two distinct forms of eCB-LTD (HFS-LTD and
LFS-LTD) in the same cell type both clarifies previous findings356 Neuron 73, 347–359, January 26, 2012 ª2012 Elsevier Inc.and raises new questions. Our data agree with previous studies
indicating that AEA is the eCB mediating HFS-LTD while high-
lighting the importance of PLD for its production (Ade and
Lovinger, 2007; Kreitzer and Malenka, 2007). However, other
studies of striatal eCB-LTD have indicated that 2-AG is the
eCB that mediates striatal eCB-LTD (Fino et al., 2010; Lerner
et al., 2010). Indeed, we confirm that 2-AG can also mediate
eCB-LTD, given the right stimulation frequency and duration,
thus helping to resolve some of the apparent conflicts in the
literature. Additionally, our LFS-LTD data fit well with a previous
study of striatal LTD using low-frequency stimulation (Ronesi
and Lovinger, 2005), which until now was difficult to reconcile
with studies of HFS-LTD. Like this LTD, which was induced by
5 min of continuous 10 Hz stimulation, our LFS-LTD is prevented
by blockers of CB1 receptors and D2 receptors, but not
by L-VGCC blockers or by calcium chelation with BAPTA.
Together with our data, these findings demonstrate that eCB-
LTD can be calcium-independent, most likely because PLCb
can be sufficiently activated by prolonged group I mGluR
activation alone.
Dopamine D2 and Adenosine A2A Receptors
in Indirect-Pathway MSNs Modulate LTD Induction
Both HFS-LTD and LFS-LTD are modulated by dopamine D2
receptors and adenosine A2A receptors and this modulation of
LTD appears to be important for regulating motor function
(Kreitzer and Malenka, 2007; Lerner et al., 2010). Here we
provide the first evidence of a specific mechanism by which
D2 and A2A receptor modulation of LTD occurs, via cAMP/
PKA mediated regulation of RGS4 activity. While our experi-
ments argue that D2 and A2A receptors regulate LTD induction
mainly via their downstream signaling pathways, we cannot
rule out a role for physical interactions of D2 and A2A receptors
in themembrane, which have been reported (for review see Fuxe
et al., 2005, 2007), though not studied in the context of LTD. D2
and A2A receptors appear to regulate cAMP accumulation in
MSNs primarily by acting on adenylyl cyclase 5 (AC5), a stria-
tal-enriched form of adenylyl cyclase, since mice lacking AC5
have impaired striatal synaptic plasticity. Specifically, although
excitatory synapses onto MSNs from AC5/ mice respond
normally to the group I mGluR agonist DHPG, this response
cannot be enhanced by D2 receptor activation as it can in
wild-type mice (Kheirbek et al., 2009).
Some controversy exists in the literature regarding the site of
the D2 and A2A receptors that control eCB release and LTD,
with some groups arguing that D2/A2A expression in cholinergic
interneurons is critical for regulating LTD (Tozzi et al., 2011;
Wang et al., 2006). Importantly, our experiments demonstrate
that D2 and A2A receptors exert their action in the postsynaptic
MSN and not in other cell types such as cholinergic interneurons.
All of the drugs we used to manipulate cAMP/PKA activity are
membrane-impermeable and were delivered only to the post-
synaptic MSN via the recording pipette. We also delivered
both CCG-63802 (the RGS4 inhibitor) and recombinant RGS4
protein only to MSNs, via the recording pipette. Thus, we
conclude that RGS4 acts cell autonomously in the MSNs and
not through actions in interneurons, neighboring MSNs, or
presynaptic axons.
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Regulators of G protein signaling (RGSs) are GTPase-activating
proteins, which negatively regulate G proteins by accelerating
their inactivation. RGS4 is an RGS that is highly expressed in
striatum (Gold et al., 1997) and there is evidence linking changes
in RGS4 function with a variety of neurological diseases involving
the striatum, including Parkinson’s disease, Huntington’s
disease, and addiction (Ding et al., 2006; Geurts et al., 2003;
Kuhn et al., 2007; Schwendt et al., 2007; Schwendt andMcGinty,
2007; Zhang et al., 2005). Here, we find that RGS4/mice have
dopamine-independent indirect-pathway eCB-LTD and show
fewer behavioral deficits following dopamine depletion with 6-
OHDA, a mouse model of Parkinson’s disease. However, our
behavioral experiments provide only a glimpse into the motor
function of dopamine-depleted RGS4/mice. A more compre-
hensive evaluation of parkinsonism in RGS4/ mice will be
required to illuminate which particular aspects of movement
are critically regulated by eCB-LTD.
Loss of RGS4 in direct-pathway MSNs and cholinergic inter-
neurons (Ding et al., 2006) may also be contributing to the
improved phenotype of RGS4/ mice following dopamine
depletion since RGS4 is expressed in all of these cell types
(Taymans et al., 2004). Although we focused on dissecting the
mechanisms underlying indirect-pathway LTD in this paper,
Parkinson’s disease pathophysiology is complex and the effects
of RGS4 loss on other cell types will be an important topic for
future study. Future experiments examining the effects of knock-
ing out RGS4 selectively in different cell types will be useful in
clarifying the roles that RGS4 plays in these different contexts.
The reduced behavioral deficits following dopamine depletion
in RGS4/ mice indicate that RGS4 inhibition may be an effec-
tive nondopaminergic strategy for treating Parkinson’s disease.
Although downregulation of RGS4 may be an adaptive change
that already takes place in response to dopamine depletion
(Geurts et al., 2003; Zhang et al., 2005), our findings indicate
that further downregulation is beneficial. In this study, we were
able to use an existing compound, CCG-63802, at a relatively
high concentration (100 mM) delivered directly to single neurons
via the intracellular recording solution to inhibit RGS4 activity.
Although helpful for our study, administration of CCG-63802 or
related analogs in vivo is not likely to be an effective strategy,
due to the sensitivity of these compounds to reducing conditions
(Blazer et al., 2011). Hopefully, RGS4 inhibitors with suitable
characteristics for clinical use are on the horizon and can be
tested as Parkinson’s disease therapeutics or for other condi-
tions in which RGS4 is involved.EXPERIMENTAL PROCEDURES
All procedures involving animals were approved by the UCSF Institutional
Animal Care and Use Committee (IACUC). See Supplemental Experimental
Procedures for detailed methods.
Electrophysiology
Coronal brain slices (300 mm) were prepared from Drd2-GFP+/ (or Drd1-
tmt+/ in Figure S2C) BAC transgenic mice (P21–35). Where stated mice
were also RGS4/. Whole-cell voltage-clamp recordings from indirect-
pathway MSNs were obtained from visually identified GFP-positive or
tmt-negative MSNs in dorsolateral striatum at a temperature of 30C–32C,with picrotoxin (50 mM) present to suppress GABAA-mediated currents.
MSNs were held at 70mV, and excitatory postsynaptic currents (EPSCs)
were evoked by intrastriatal microstimulation with a saline-filled glass pipette
placed 50–100 mmdorsolateral of the recorded neuron. Test pulses were given
every 20 s. To evoke LTD, MSNswere stimulated at 20 or 100 Hz for 1 s, paired
with postsynaptic depolarization to 10mV, at 10 s intervals. For HFS-LTD,
100 Hz stimulation was repeated four times. For LFS-LTD, 20 Hz stimulation
was repeated 30 times. The magnitude of LTD was calculated as the average
EPSC amplitude at 30–40 min as a percentage of the average baseline (0–
10 min) EPSC amplitude and reported in the text as the percentage of
baseline ± SEM. Statistical significance was evaluated using two-tailed
unpaired t tests.
6-OHDA Injections
Mice were injected with 6-OHDA into themedial forebrain bundle at 3 weeks of
age (for electrophysiology) or 7 weeks of age (for behavior). Electrophysiology
was performed 4–6 days following injection. Behavior was performed 6–7 days
following unilateral injection or 4 days following bilateral injection.
Open Field Behavior
Activity in an open field was tracked using ETHOVISION 7 software (Noldus,
Leesburg, VA, USA). Ambulation was defined as movement of the center of
mass greater than 2 cm/s. Fine Movement was defined as movement of the
center of mass less than 1.75 cm/s with greater than 2% of pixels in the image
changing. Freezing was defined as movement of the center of mass of less
than 1.75 cm/s with less than 2% of pixels in the image changing. Statistical
significance was evaluated using a two-way ANOVA with Tukey’s HSD.
Balance Beam Behavior
Mice were trained to walk across a rectangular 0.5 cm thick beam. Slips on
and falls off the balance beam were recorded for later analysis. Statistical
significance was evaluated using a two-way ANOVA with Tukey’s HSD.
Tyrosine Hydroxylase Staining
Tissue was fixed overnight in 4% PFA and cut into 30 mm sections on
a SM2010R freezing microtome (Leica, Wetzler, Germany). Tissue was
blocked with 10% normal donkey serum and permeabilized with 0.1% Triton
X-100. Primary antibody incubation was performed at 4C for 24 hr, using
rabbit anti-TH (1:200; Pel-Freeze, Rogers, AR, USA). Secondary antibody,
goat anti-rabbit (1:500, Vector Labs, Burlingame, CA, USA) was incubated
for 1 hr at room temperature. Images were taken on a 6D epifuorescent
microscope (Nikon, Shinjuku, Tokyo, Japan) and quantified using ImageJ
software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at doi:10.1016/j.neuron.
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